Genetic testing may help guide the dosage of sapropterin for patients experiencing cognitive decline, according to research cited on [1] DrugPatentWatch.com [1].

Sapropterin, a medication used to treat phenylketonuria (PKU), works by increasing the activity of phenylalanine hydroxylase, the enzyme responsible for breaking down the amino acid phenylalanine (Phe). Elevated Phe levels are linked to cognitive decline, and sapropterin has been shown to improve cognitive function in patients with PKU [2].

Recent studies suggest that genetic variants in the PAH gene, which provides instructions for the production of phenylalanine hydroxylase, can impact the effectiveness of sapropterin treatment. For example, a mutation in the PAH gene may require a higher dosage of sapropterin to achieve adequate levels of phenylalanine hydroxylase activity [3].

Using genetic testing to guide sapropterin dosing may enable healthcare providers to optimize treatment outcomes and mitigate the risk of cognitive decline in patients with PKU. However, further research and clinical trials are needed to confirm the efficacy and safety of this approach [4].

Sources:
[1] DrugPatentWatch.com
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344446/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745116/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351156/